At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,945 enrolled
Drug / intervention
Azilsartan Medoxomildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
International Multicentre, Observational, Non-Interventional Prospective Study of Azilsartan Medoxomil in Patients With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan
In Brief
An observational study evaluating Azilsartan Medoxomil for Hypertension. Completed, enrolled 1,945 participants across 66 sites in 2 countries.
Detailed Summary
The purpose of this study is to estimate antihypertensive effect of azilsartan medoxomil (Edarbi®) therapy on blood pressure in participants with overweight or obesity in routine clinical practice of hypertension (HTN) treatment in the Russian Federation and in the Republic of Kazakhstan..
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesKazakhstan, Russia
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedApr 2016
Enrollment StartJul 2016
Primary CompletionMay 2018
TodayJul 2026
First PostedApr 29, 2016
Enrollment StartJul 18, 2016
Primary CompletionMay 8, 2018
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 10.2 years ago
Interventions
Azilsartan Medoxomildrug
Azilsartan medoxomil tablets